Medical Pharmacology: Adrenenergic Autonomic pharmacology

**Epinephrine: Basic Pharmacology and Clinical Uses**
Epinephrine

Attribution: Med Immersion: "Epinephrine (A Mini-Lecture in the Direct-Acting Adrenergic Agonist Series." https://www.youtube.com/watch?v=4uuoLTp5BEE Med Immersion Youtube Channel: https://www.youtube.com/c/MedImmersion/featured

Absorption⁴

Epinephrine undergoes rapid oxidation and conjugation in the liver following oral administration.
Therefore, for clinical effectiveness, other routes of administration must be utilized.
α-adrenergic receptor agonist properties of epinephrine cause localized vasoconstriction, which limits subcutaneous epinephrine absorption.
- Improved absorption can be obtained by intramuscular administration.
Both subcutaneous and intramuscular epinephrine injection are utilized for treatment of anaphylaxis.⁷¹
- The subcutaneous route is often favored for "mild" reactions.

In the initial treatment of anaphylaxis, research findings suggest intramuscular epinephrine injection into the thigh is preferable compared to upper arm intramuscular or subcutaneous routes of administration. This conclusion was reached because peak plasma epinephrine concentration was higher following thigh administration (see figure below).⁷¹

**Mean plasma epinephrine concentrations vs time following administration of 0.3 mg dose of epinephrine by i.m or s.c injection⁷¹**

"Mean plasma epinephrine concentrations versus time are shown after administration of an identical 0.3-mg (0.3-mL) dose of epinephrine by IM or SC injection in 2 different sites. T, Thigh; A, upper arm. Mean endogenous plasma epinephrine concentrations are shown after IM or SC injection of 0.9% saline solution (0.3 mL) in the upper arm. The plasma epinephrine concentrations shown were calculated by averaging (mean ± SEM) the epinephrine concentrations at each sampling time for each route and each site of injection."⁷¹

Metabolism:

Epinephrine undergoes rapid metabolism which results in its inactivation.
The hepatic enzymes monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) are particularly important in epinephrine inactivation.

Monoamine oxidase catalyzes monoamine oxidative deamination. In a reaction that consumes oxygen, an amine group is removed forming the corresponding aldehyde and ammonia.

Monoamine oxidase enzymes contain a covalently linked cofactor FAD (flavin adenine dinucleotide) and therefore described as flavoproteins. The form of the reaction is shown below:⁷²
MAO/FAD catalyzed monoamine deamination reaction⁷²

**Flavin Adenine Dinucleotide (FAD): Ball & Stick Model (top) and Space Filling Model (Bottom)**⁷²

Ribbon diagram of a monomer of human MAO-A, with FAD and clorgiline bound, oriented as if attached to the outer mitochondrial membrane⁷²

Inactivation of epinephrine and catecholamine neurotransmitters such as dopamine and norepinephrine also involves catechol-O-methyltransferase (COMT), an enzyme discoverd by Julius Axelrod in 1957.⁷³

Methyltransferase enzymes catalyze methyl (CH₃)-group transfers with the methyl group in this case provided by S-adenosyl-methionine (SAM).

**Catechol-O-methyl transferase^77,77a**

COMT complex with 3,5-dintrocatechol (dark blue) and S-adenosyl-methionine (yellow), created using PyMol and GIMP.^77,77a

COMT inhibitors such as tocapone (Tasmar, administered in combination with levodopa and carbidopa (Sinemet) and entacapone (Comtan, administered in combination with levodopa and carbidopa ) are used in management of Parkinson's disease. Entacapone does not exhibit anti-Parkinson's effects on its own.
- In August 2010 the FDA notified healthcare professionals that evaluation of clinical trial data indicating patients taking a combination of carbidopa/levodopa and entacapone (the combination drug was Stalevo) might be an increased risk for cardiovascular events including heart attack, stroke, and cardiovascular death, compared to patients taking the combination product Sinemet (carbidopa + levodopa), was undertaken. It is suggested that the reader follow-up on the current status of this FDA evaluation.⁷⁴
Dopamine Degradation⁷⁵
Norepinephrine Degradation⁷⁶

Formulation and stability⁴
- Various epinephrine formulations are available to accommodate differing routes of administration and/or clinical indications.
  - Epinephrine administration may involve:
    - Subcutaneous injection
    - Intramuscular injection
    - Intravenous infusion
    - Topical application
    - Inhalation.
  - The intravenous route provides immediate effect and is administered cautiously with adequate dilution and slow injection.
  - Epinephrine suspensions are available to slow subcutaneous absorption and this preparation should not be injected intravenously.
  - Furthermore, the 1% (10 mg/ml; 1:100) formulation for use by inhalation must not be confused with the 1:1000 solution appropriate for parenteral use.
    - Possible fatal consequences can ensue if 1:100 epinephrine solution is administered parenterally.
  - Epinephrine is well known to be unstable and alkaline solution if exposed to air or light. Oxidation of epinephrine is indicated by a pink color (adrenochrome); subsequent polymer formation results in a brown appearance.

Some clinical applications⁴

A major clinical use for epinephrine is in prompt management of hypersensitivity reactions to drugs and other allergens. Indications include treatment of anaphylaxis.⁴
Cardiac uses include helping to restore normal cardiac rhythm in patients in cardiac arrest..⁴
- Epinephrine is the drug of choice for treating patients in cardiac arrest.^4,58
  - Vasopressin may be considered if arrest continues following the first dose of epinephrine and vasopressin is considered a possible option to epinephrine.
  - Vasopressin
- In patients presenting with persistent ventricular fibrillation, amiodarone is likely the antiarrhythmic agent of choice, although its administration should be preceded by at least one epinephrine dose.
  - Epinephrine activates both α- and β-adrenergic receptors; however, the important epinephrine actions in this context appear mediated by α-receptor activation.
- Mechanism of Action: The mechanism of action is based on epinephrine-mediated increases in systemic vascular resistance which secondarily improves both coronary and cerebral perfusion.
  - Epinephrine administration along with β-adrenergic receptor antagonists proved helpful in resuscitation; whereas, epinephrine coadministration with α-receptor blockers were not helpful.⁵⁸
  - β-adrenergic effects associated with epinephrine may precipitate, with repeated doses, recurrent ventricular arrhythmias; as a result, intravenous β-adrenergic receptor antagonists might be ineffective antiarrhythmic intervention during resuscitation should several epinephrine doses be administered.
  - Concerning vasopressin: this nonadrenergic peripheral vasoconstrictor has been recommended for use during cardiac arrest, although in two randomized clinical trials no increase in Return of Spontaneous Circulation (ROSC) was noted, when vasopressin was compared to 1 mg epinephrine.⁵⁸
Vasocontrictors added to local anesthetic solutions⁷⁸
- Purpose of adding epinephrine to a local anesthetic solution: Increased duration: addition of epinephrine (1:2000,000 or 5 μg/ml) to cause vasoconstriction
  - Reduced systemic absorption
  - Higher anesthetic concentration near nerve fibers
  - Prolongation of conduction blockade (about 50% longer)
  - Reduced systemic absorption (by about 33%)
- Factors influencing the effectiveness of epinephrine on local anesthesia: Dependencies --
  - Which anesthetic is used:
    - Reduced effect of epinephrine on duration of conduction blockade and systemic absorption comparing mepivacaine (Carbocaine) and etidocaine (Duranest) [these are more lipophilic] with lidocaine (Xylocaine), which is less lipophilic
      - More lipophilic local anesthetics will tend on their own to associate strongly with tissues
  - Level of sensory blockade needed for spinal or epidural anesthesia
    - Duration of lower extremity sensory anesthesia extended by epinephrine or phenylephrine (Neo-Synephrine); this effect is not observed for abdominal region anesthesia
      - Conditions: epinephrine (0.2 mg) or phenylephrine (Neo-Synephrine) (2 mg) added to mepivacaine (Carbocaine) or lidocaine (Xylocaine), placed in subarachnoid spaces
  - Spinal anesthesia - tetracaine (pontocaine): duration of action extended by vasoconstrictors
    - Condition 1: epinephrine plus tetracaine (pontocaine) (6 mg, low-dose)- result: increase in spinal anesthesia success rate
    - Condition 2: epinephrine plus tetracaine (pontocaine) (10 mg, higher dose)- result: no increase in spinal anesthesia success rate
- Prolongation of local anesthetic action (no effect by epinephrine on time-to-onset): Mechanisms --
  - Decreased systemic absorption
  - Increased local anesthetic concentration in the vicinity of sensory nerves
  - Increased uptake of the local anesthetic
- Advantages of reduced local anesthetic systemic absorption:
  - Local anesthetic absorption rate more likely to match metabolic rate resulting in less local anesthetic systemic toxicity
- Toxicities associated with systemic epinephrine absorption:
  - Local anesthetic + epinephrine: increased cardiac irritability which may cause an increased risk of cardiac arrhythmias
  - Increased possibility of hypertensive response in susceptible patients
- Other agents which may be added to local anesthetics that affect duration of action
  - Dextran (low-molecular-weight) when added to local anesthetic solutions result in increased peripheral nerve block anesthesia duration (probably due to a reduction in local anesthetic systemic absorption)
Powerful vasoconstrictive actions of epinephrine, mediated by α₁-adrenergic receptor activation, is the basis for effectiveness as a topical hemostatic agent.
- Bleeding surfaces in the mouth or bleeding peptic ulcers (visualized endoscopically) may be managed by epinephrine.

**Some Contraindications to Vasoconstrictor Use and/or Local Anesthetic Drugs**⁷⁹
Recent myocardial infarction (heart attack) (<1 month or symptomatic) Presence of "high-risk" arrhythmia Uncontrolled or severe hypertension Unstable angina Patients receiving digitalis glycosides (e.g. digoxin) Uncontrolled diabetes Uncontrolled hyperthyroidism Moderate to severe asthma (avoid sulfite-containing local anesthetic preparations) Documented "allergy" to anesthetic or vasoconstrictor drug Pheochromocytoma Drug abuse--cocaine, methamphetamine, amphetamine (known use within prior 6-24 hour minimum, depending on agent ingested

**Some Relative Contraindications to Vasoconstrictor Use and/or Local Anesthetic Drugs**⁷⁹
Disease or Drug Issue	Selection Consideration
Stroke history	limit vasoconstrictor
Cardiovascular conditions; and/or patient taking nonselective beta antagonists, antihypertensive drugs.	limit vasoconstrictor
Hypoglycemic agents, insulin	limit vasoconstrictor
Hyperthyroidism	limit vasoconstrictor
Monoamine oxidase inhibitors (MAO inhibitors)	limit vasoconstrictor
Anticonvulsants, e.g. phenytoin	limit vasoconstrictor

Epinephrine inhalation may be helpful in management of post-intubation and infectious croup.⁴

References
Hoffman, B.B and Lefkowitz, R.J, Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists, In Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp.199-242 Stoelting, R.K., "Sympathomimetics", in Pharmacology and Physiology in Anesthetic Practice, Lippincott-Raven Publishers, 1999, p. 260 Carotic Baroreceptors: CRRx: Mediine ReEnvisioned http://www.cvrx.com/patients/index.php?id=41 Westfall, TC and Westfall DP Adrenergic Agonists and Antagonists in Goodman and Gilman's The Pharmacological Basis of Therapeutics, eleventh editions, (Brunton LL, Lazo JS and Parker KL, eds), McGraw-Hill Medical Publishing Division, New York, 237-295, 2006. Catecholamine Biosynthesis: The Interactive Library; Edinformatics.com: http://www.edinformatics.com/interactive_molecules/info/adrenaline.htm . Standaert DG and Young AB Treatment of Central Nervous System Degenerative Disorders In Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp536-537. Adrenergic Neuronal Diagram adapted from http://www.drugabuse.gov/pubs/teaching/Teaching4/Teaching.html Guanetidine (Ismelin™, brand name not available in the U.S.) pharmacology: Clinical Pharmacology, RxList: The Internet Drug Index, http://www.rxlist.com/ismelin-drug.htm . Williams FM and Turner TJ Adrenergic Pharmacology in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd Edition (Golan DE, Tashijan Jr AH, Armstrong EJ and Armstrong AW, eds) Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, 129-144, 2008. Moss J and Glick D Autonomic Function in Anesthetic Pharmacology: Physiological Principles and Clinical Practice: A Companion to Miller's Anesthesia (Evers AS and Maze M, eds) Churchill Livingstone, Philadelphia, Chapter 14, 209-226, 2004. Presynaptic Proteins, Synaptic Vesicle Docking and Membrane Fusion, http://neuromuscular.wustl.edu/pathol/snare.htm#cachan, Neuromuscular Disease Center, Washington University, St. Louis, MO USA (http://neuromuscular.wustl.edu/index.html) Sudhof TC The Synaptic Vesicle Cycle, Annual Review of Neuroscience, July 200, Vol. 27, pp 509-547. Phenochomocytoma picture (http://health-pictures.com/pheochromocytoma.htm); Geneva Foundation of Medical Education and Research, Pheochromocytoma, http://www.gfmer.ch/selected_images_v2/detail_list.php?cat1=1&cat2=113&cat3=22&cat4=2&stype=n . Brown H, Goldberg PA, Selter JG, Cabin HS, Marieb NJ, Udelsman R and Setaro JF Hemorrhagic Pheochromocytoma Associated with Systemic Corticosteroid Therapy and Presenting as Myocardial Infarction with Severe Hypertension. Clinical Case Seminar, J Clin Endocrinol Metab 2005 90: 563-569. (http://jcem.endojournals.org/cgi/content/full/90/1/563). "Clevidine (Cleviprex) for IV Treatment of Severe Hypertension", Table 1. Some Parenteral Drugs for Hypertensive Emergencies. The Medical Letter^® on Drugs and Therapeutics, Volume 50 (Issue 1295) September 22, 2008. Katzung, BG Introduction to Autonomic Pharmacology (Section II: Autonomic Drugs) in: Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 75-92, 2007. Sympathetic Nerve Pathway: Neuroeffector Junction ("Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved"); PharmGKb modified slightly to highlight uptake1, uptake-2, uptake 1 block, and location of intravesicular norephinephrine synthesis. (Pharmacogenomics Knowledge Base). http://www.pharmgkb.org/search/pathway/neurotransmitter/neuroeffector.jsp . T.E. Klein, J.T. Chang, M.K. Cho, K.L. Easton, R. Fergerson, M. Hewett, Z. Lin, Y. Liu, S. Liu, D.E. Oliver, D.L. Rubin, F. Shafa, J.M. Stuart and R.B. Altman, "Integrating Genotype and Phenotype Information: An Overview of the PharmGKB Project" (220k PDF), The Pharmacogenomics Journal (2001) 1, 167-170. Tellioglu T, Robertson D (November 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Rev Mol Med 2001: 1–10. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V (Aug 1998). "Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta". J Biol Chem 273 (26): 15971–9. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S. (Jun 2006). "Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.". Neuropharmacology 50 (8): 941–952. Bourne HR and von Zastrow M "Drug Receptors and Pharmacodyamics" Chapter 2 in Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 17-27, 2007. Muller M Lecture Material Online: Lecture 6: "Cellular Communication" http://www.uic.edu/classes/bios/bios100/summer2003/lect06.htm. Bowman T and Jove R STAT Proteins and Cancer: From the Molecular Oncology Program at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida http://www.moffitt.org/moffittapps/ccj/v6n6/dept6h.htm . Tong L, Warren TC, King J, Betageri R, Rose J, Jakes S (March 1996). "Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution". J. Mol. Biol. 256 (3): 601–10. Sadowski I, Stone JC, Pawson T (December 1986). "A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps". Mol. Cell. Biol. 6 (12): 4396–4408. Russell RB, Breed J, Barton GJ (June 1992). "Conservation analysis and structure prediction of the SH2 family of phosphotyrosine binding domains". FEBS Lett. 304 (1): 15–20. von Zastrow M and Bourne HR "Drug Receptors and Pharmacodynamics" Chapter 2 in Basic and Clinical Pharmacology (11th edition), (Katzung BG, Masters, SB and Trevor AJ, eds) McGraw-Hill Medical , New York, on-line version (Access Medicine) 2009. Powledge TM (2004) Nicotine as Therapy. PLoS Biol 2(11): e404. doi:10.1371/journal.pbio.0020404 (http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.0020404) Green T, Heinemann SF and Gusella JF Molecular Neurobiology and Genetics: Investigation of Neuron Function and Dysfunction (Review) Neuron, Vol. 20, 427-444, March, 1998 (Cell Press (c), 1998). Unwin N Nicotinic acetylcholine receptor at 9 Å resolution. J. Mol. Biol. 229, 1101-1124. Eyford, T Adenylyl cyclase http://proteopedia.org/wiki/index.php/Adenylyl_cyclase . 31 a. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem. 1999 Mar 19;274(12):7599-602. 31 b, Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature. 1997 Mar 20;386(6622):247-53. Goodsell DS illustrator, The Scrips Research Institute, public domain work, http://en.wikipedia.org/wiki/Adenylate_cyclase . Ranganathan R, Ross E (1997). "PDZ domain proteins: scaffolds for signaling complexes.". Curr Biol 7 (12): R770–3 PDZ domain http://en.wikipedia.org/wiki/PDZ_domain Biaggioni I and Robertson D Adrenoceptor Agonists & Sympathomimetic Drugs (Chapter 9) in in Basic and Clinical Pharmacology (11th edition), (Katzung BG, Masters, SB and Trevor AJ, eds) McGraw-Hill Medical , New York, on-line version (Access Medicine) 2009. Korte E "PIP2 cleavage by PLC to release IP3 and DAG", public domain, http://en.wikipedia.org/wiki/File:PIP2_cleavage_to_IP3_and_DAG.jpg . McVary KT A review of combination therapy in patients with benign prostatic hyperplasia, Clinical Therapeutics 2007 29 (3): 387-398. Caine M The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4. Shapiro E Hartanto V and Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992; 21: 297-307. Brittsan AG and Kranias EG Review: Phosphlakmban and Cardiac Contractile Function. J. Mol Cell Cardiol 32. 2131-2139. Lomize A Phospholamban Pentamer, protein image from OPM database, public domain media (http://en.wikipedia.org/wiki/File:1zll_opm.gif) Foex P and Highan H. Myocardial Performance: Physiological Principles and Clinical Practice: A Companion to Miller's Anesthesia (Evers AS and Maze M, eds) Churchill Livingstone, Philadelphia, Chapter 14, 284-2285, 2004. 42(a) Weiss HR Effect of coronary artery occlusion on regional arterial and venous O₂ saturation, O₂ extraction, blood flow and O₂ consumption in the dog heart. Circulation Research 47(3) 400-407, September 1980. Khouri EM Gregg DE and Rayford CR Effect of exercise on cardiac output, left coronary flow and myocardial metabolism in the unanesthetized dog. Circulation Research 17(5) 327-437, November 1965. Epicardial Vessels: Gray's Anatomy, 20th U.S. edition of Gray's Anatomy of the Human Body, originally publishedin 1918, public domain. Beta-2 Adrenergic Receptor, figure public domain (http://en.wikipedia.org/wiki/File:2RH1.png); original crystallographic citations: 45 (a) Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007). "High-resolution crystal structure of an engineered human β₂-adrenergic G protein-coupled receptor". Science 318 (5854): 1258–65. 45 (b) Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007). "GPCR engineering yields high-resolution structural insights into β₂-adrenergic receptor function". Science 318 (5854): 1266–73. Westfall, TC and Westfall DP Neurotransmission: The Autonomic and Somatic Motor Nervous System in Goodman and Gilman's The Pharmacological Basis of Therapeutics, eleventh editions, (Brunton LL, Lazo JS and Parker KL, eds), McGraw-Hill Medical Publishing Division, New York, 137-181, 2006. Emorine LJ Marullo S Briend-Sutren MM Patey G Tate K Delavier-Klutchko C Strosberg AD Molecular characterization of the human β₃-adrenergic receptor. Science, Vol. 245, No. 4922, Sep. 8, 1989, pp. 1118-1121. Walston J Silver K Bogardus C Knowler W Celi FS Austin S Manning B Strosberg AD Stern MP Raben N Sorkin JD Roth J Shuldiner AR Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β₃-adrenergic receptor gene. New England J. of Medicine, Vol. 333 No. 6, August 10, 1995, pp. 343-347. Hoffman BB Adrenoceptor-Activating & Other Sympathomimetic Drugs in: Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 121-140, 2007. Goodsell, DS, Tyrosine Hydroxylase, The Scripps Research Institute, public domain image, http://en.wikipedia.org/wiki/File:Tyrosine_Hydroxylase.png . Chemical Synapse, http://schools-wikipedia.org/wp/c/Chemical_synapse.htm . Frang H Cockcroft V Karskela T Scheinin M Marjamaki A Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors JBC, 276, 31279-31284, June 6, 2001. http://www.jbc.org/content/276/33/31279.full Barrett KE Barman SM Boitano S Brooks H "The Adrenal Medulla & Adrenal Cortex" in: Ganong's Review of Medical Physiology, 23e, Chapter 22, on-line version, 2010. Achermann JC and Jameson JL "Disorders of Sex Development" in Harrison's Principles of Internal Medicine (eds, Fauci AS Braunwald E Kasper DL Hauser SL Longo DL Jameson JL Loscalzo J), 17th edition, pp 2345-2346, 2008, McGraw-Hill Medical, New York. Goldenberg M Aranow H Jr Smith AA Faber M Pheochromocytoma and essential hypertensive vascular disease. Arch. Intern. Med. 86: 823-826, 1950. Carrim YO "The Cardiovascular system, heart muscle; The heart as a pump." http://samedical.blogspot.com/2010/08/heart-muscle-heart-as-pump.html . "Madhero88" "A graphical representation of the electrical conduction system of the heart showing the sinoatrial node, atrioventricular none, bundle of His, Purkinje fibers and Bachmann's bundle, http://en.wikipedia.org/wiki/File:ConductionsystemoftheheartwithouttheHeart.png . Ewy GA Cardiopulmonary and Cardiocerebral Resuscitation, Chapter 50, in Hurst's The Heart, 12th edition (eds, Fuster V O'Rourke RA Wash RA Poole-Wilson P; associate eds: King II SB Roberts R Nash IS Prystowsky EN; Editors of the online edition: senior editors: Walsh RA and Simon DI; associate Editors; Hoit BD Fang JC Costa M), 2008, on-line edition. 58a. American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 2005; 112 (Suppl IV): IV-1-IV-211. Mohrman DE and Heller LJ "Vascular Control" Chapter 7, in Cardiovascular Physiology, 6th edition, The McGraw-Hill Companies, Inc, 2006, on-line edition. Stoelting, RK and Dierdorf, SF, "Asthma" in Anesthesia and Co-Existing Disease, 4th edition, Chapter 14, pp 194-204, Churchill-Livingstone, Philadelphia, 2002 60a. Kingston, HGG, Hirshman, CA Perioperative management of the patient with asthma. Anesth Analg 1984; 63: 844-55. (second sourced from reference 1) Roisen, MF, "Anesthetic Implications of Concurrent Diseases" in Anesthesia, 5th edition, (Miller, R.D, editor), Chapter 25, pp 996-997, Churchill-Livingstone, Philadephia 2000. Barrett KE Barman SM Boitano S Brooks H "Endocrine Functions of the Pancreas & Regulation of Carbohydrate Metabolism" in: Ganong's Review of Medical Physiology, 23e, Chapter 21, on-line version, 2010. Narayanese and YassineMrabet, Citric acid cycle (Tricarboxylic acid cycle), public domain, GNUU Free Documentation License, http://en.wikipedia.org/wiki/Citric_acid_cycle . Elayat AA, el-Naggar MM, Tahir M (1995). "An immunocytochemical and morphometric study of the rat pancreatic islets". Journal of Anatomy 186 (Pt 3): 629–37. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1167020/pdf/janat00134-0170.pdf) 64a. Islets of Langerhans; http://en.wikipedia.org/wiki/Islets_of_Langerhans Süß C Sukale J Solima M "light microscopy of a paraffin embedded mouse islet; labels: insulin green, glucagon red, nuclei blue" Solimena Lab, Med. Fac., University of Technology, Dresden, Germany. http://en.wikipedia.org/wiki/File:Mouse_islet_LM_SolimenaLab.jpg . http://en.wikipedia.org/wiki/File:PDB_3tgl_EBI.jpg courtesy: http://www.ebi.ac.uk/ Chapus C, Rovery M, Sarda L, Verger R (1988). "Minireview on pancreatic lipase and colipase". Biochimie 70 (9): 1223–1234. Barrett KE Barman SM Boitano S Brooks H "General Principles & Energy Production in Medical Physiology in: Ganong's Review of Medical Physiology, 23e, Chapter 1, on-line version, 2010. Austgen L and Bowen R "Brown Adipose Tissue" http://www.vivo.colostate.edu/hbooks/pathphys/misc_topics/brownfat.html . Ropper AH and Samuels MA "Ion Channel Disorders: The periodic paralyses and hereditary nondystrophic mytonias (Channelopathies) in Adams & Victor's Principles of Neurology, 9e, 2009, online edition. Estelle F Simons R Gu X and Simons KJ Epinephrine absorption in adults: Intramuscular versus subcutaneous injection J Allergy Clin Immunol 2001; 108: 871-873. Flavine Adenine Dinucleotide (FAD) public domain images http://en.wikipedia.org/wiki/Flavin_adenine_dinucleotide . Axelrod J (August 1957). "O-Methylation of Epinephrine and Other Catechols in vitro and in vivo". Science 126 (3270): 400–1. Entacapone PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000168 . Dopamine Degradation by "Neurotiker", public domain image, http://en.wikipedia.org/wiki/File:Dopamine_degradation.svg . Haggstrom M Breakdown of norepinephrine, public domain inkscape http://en.wikipedia.org/wiki/File:Noradrenaline_breakdown.svg . Fvasconcellos "Cartoon diagram of human catechol-O-methyl transferase (COMT) in complex with S-adenosyl methionine and 3,5-dinitrocatechol; public domain drawing. 77a. Rutherford K, Le Trong I, Stenkamp RE, Parson WW (June 2008). "Crystal structures of human 108V and 108M catechol O-methyltransferase". J Mol Biol 380 (1): 120–30, http://www.rcsb.org/pdb/explore/explore.do?structureId=3BWM . Stoelting, R.K., "Local Anesthetics", in Pharmacology and Physiology in Anesthetic Practice, Lippincott-Raven Publishers, 1999, pp 158-181. Parrmann C Decision Making and Local Anesthesia Dimensions of Dental Hygiene, October 2008; 6(10): 24. http://www.dimensionsofdentalhygiene.com/ddhright.aspx?id=2384